Annual Report 2009 - Daiichi Sankyo

More documents

Recommendations

Info

CORPORATE INFORMATION Major Group Companies (Consolidated Subsidiaries) Paid-in Equity Owned Company Country Capital by the Parent Principal Activities (Thousands) Company (%) (As of June 2009) DAIICHI SANKYO PROPHARMA CO., LTD. Japan ¥100,000 100.0 Manufacturing of pharmaceuticals DAIICHI SANKYO RD ASSOCIE CO., LTD. Japan ¥50,000 100.0 Support of research and development of the Group DAIICHI SANKYO BUSINESS ASSOCIE CO., LTD. Japan ¥50,000 100.0 Business support of the Group DAIICHI SANKYO HAPPINESS CO., LTD. Japan ¥50,000 100.0 Business support of the Group DAIICHI SANKYO LOGISTICS CO., LTD. Japan ¥50,000 100.0 Distribution and related affairs DAIICHI SANKYO CHEMICAL PHARMA CO., LTD. Japan ¥50,000 100.0 Manufacturing of active pharmaceutical ingredients and intermediates DAIICHI SANKYO HEALTHCARE CO., LTD. Japan ¥100,000 100.0 ASUBIO PHARMA CO., LTD. Japan ¥11,000,000 100.0 Manufacturing and sales of OTC drugs, cosmetics, medical equipment, food, and beverages, among others Research, development, manufacturing, and sales of pharmaceuticals DAIICHI SANKYO, INC. U.S.A. US$24,900 100.0 Research, development, and sales of pharmaceuticals Luitpold Pharmaceuticals, Inc. U.S.A. US$200 100.0 DAIICHI SANKYO EUROPE GmbH Germany EUR16,000 100.0 Manufacturing and sales of pharmaceuticals and veterinary medicine Development, manufacturing, and sales of pharmaceuticals DAIICHI SANKYO UK LTD. U.K. £19,500 100.0 Sales of pharmaceuticals DAIICHI SANKYO ESPAÑA S.A. Spain EUR120 100.0 Sales of pharmaceuticals DAIICHI SANKYO ITALIA S.p.A. Italy EUR120 100.0 Sales of pharmaceuticals DAIICHI SANKYO PORTUGAL LDA. Portugal EUR349 100.0 Sales of pharmaceuticals DAIICHI SANKYO AUSTRIA GmbH Austria EUR18 100.0 Sales of pharmaceuticals DAIICHI SANKYO (SCHWEIZ) AG Switzerland CHF3,000 100.0 Sales of pharmaceuticals DAIICHI SANKYO NEDERLAND B.V. Netherlands EUR18 100.0 Sales of pharmaceuticals DAIICHI SANKYO BELGIUM N.V.-S.A. Belgium EUR62 100.0 Sales of pharmaceuticals DAIICHI SANKYO ALTKIRCH SARL France EUR457 100.0 Manufacturing of raw materials for pharmaceuticals DAIICHI SANKYO DEUTSCHLAND GmbH Germany EUR51 100.0 Sales of pharmaceuticals DAIICHI SANKYO FRANCE SAS France EUR7,182 100.0 Sales of pharmaceuticals DAIICHI SANKYO İLAÇ TİCARET Ltd., S, ti Turkey TL5 100.0 Sales of pharmaceuticals Daiichi Sankyo Co., Ltd. Annual Report 2009 77
(As of June 2009) Paid-in Equity Owned Company Country Capital by the Parent Principal Activities (Thousands) Company (%) DAIICHI SANKYO IRELAND LTD. Ireland EUR20 100.0 Sales of pharmaceuticals DAIICHI SANKYO DEVELOPMENT LTD. U.K. £400 100.0 Development of pharmaceuticals U3 Pharma GmbH Germany EUR1,126 100.0 Research and development of pharmaceuticals SHANGHAI SANKYO PHARMACEUTICALS CO., LTD.* DAIICHI PHARMACEUTICAL (BEIJING) CO., LTD.* China US$53,000 100.0 China US$63,800 100.0 Research, development, manufacturing, and sales of pharmaceuticals Development, manufacturing, and sales of pharmaceuticals DAIICHI SANKYO HONG KONG LIMITED China HK$3,000 100.0 Marketing of pharmaceuticals DAIICHI SANKYO TAIWAN LTD. Taiwan NT$345,000 100.0 Manufacturing and sales of pharmaceuticals DAIICHI SANKYO KOREA CO., LTD. Korea WON3,000,000 100.0 Sales of pharmaceuticals DAIICHI SANKYO (THAILAND) LTD. Thailand Baht10,000 100.0 Import, sales, and agency services of pharmaceuticals and raw materials DAIICHI SANKYO BRASIL FARMACÊUTICA LTDA. Brazil BRL34,000 100.0 Manufacturing and sales of pharmaceuticals DAIICHI SANKYO VENEZUELA, S.A. Venezuela VEB10,000 100.0 Manufacturing and sales of pharmaceuticals Ranbaxy Laboratories Limited India INR2,101,800 63.9 Research, development, manufacturing, and sales of pharmaceuticals Note: In July 2009, Shanghai Sankyo Pharmaceuticals Co., Ltd., was renamed as Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd., and Daiichi Pharmaceutical (Beijing) Co., Ltd., was renamed as Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. 78 Daiichi Sankyo Co., Ltd. Annual Report 2009
Page 1 and 2:
DAIICHI SANKYO CO., LTD. Annual Rep
Page 3 and 4:
Three Years Young— See How Much W
Page 5 and 6:
CONSOLIDATED FINANCIAL HIGHLIGHTS D
Page 7 and 8:
MESSAGE FROM THE PRESIDENT “We ar
Page 9 and 10:
Our third challenge is to make stea
Page 11 and 12:
STRATEGIC MOVE 1: EXPANDING OUR BUS
Page 13 and 14:
STRATEGIC MOVE 2: GROUNDBREAKING DE
Page 15 and 16:
STRATEGIC MOVE 3: REALIZING THE HYB
Page 17 and 18:
The hybrid business model offers at
Page 19 and 20:
R&D The launch of Effient/Efient of
Page 21 and 22:
Enriching the Oncology Pipeline In
Page 23 and 24:
Development Pipeline Development Co
Page 25 and 26:
SALES AND MARKETING OPERATIONS Pres
Page 27 and 28: United States DAIICHI SANKYO, INC.
Page 29 and 30: Europe DAIICHI SANKYO EUROPE GmbH (
Page 31 and 32: Healthcare Business Striving to Rea
Page 33 and 34: CORPORATE GOVERNANCE AND INTERNAL C
Page 35 and 36: Board of Directors (As of June 26,
Page 37 and 38: CORPORATE SOCIAL RESPONSIBILITY (CS
Page 39 and 40: FINANCIAL SECTION Consolidated Fina
Page 41 and 42: ■ Japan Fiscal 2008 net sales in
Page 43 and 44: Financial Position At March 31, 200
Page 45 and 46: Consolidated Balance Sheets DAIICHI
Page 47 and 48: Consolidated Statements of Operatio
Page 49 and 50: Consolidated Statements of Cash Flo
Page 51 and 52: Held-to-maturity debt securities ar
Page 53 and 54: Accounting for Certain Lease Transa
Page 55 and 56: In the year ended March 31, 2007, t
Page 57 and 58: (2) At March 31, 2009 and 2008, car
Page 59 and 60: Future lease payments at March 31,
Page 61 and 62: Net deferred tax assets as of March
Page 63 and 64: 11. Retirement and Termination Bene
Page 65 and 66: (a) 2) Purpose of acquisition To de
Page 67 and 68: 15. Segment Information (1) Busines
Page 69 and 70: As described in note 2 to the conso
Page 71 and 72: 17. Stock Option Plans The Company
Page 73 and 74: Individuals covered by the plan: 20
Page 75 and 76: Price information of stock options
Page 77: Independent Auditors’ Report 76 D
Page 81: 3-5-1, Nihonbashi Honcho, Chuo-ku,
show all

Annual Report 2009 - Daiichi Sankyo

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?